Clinical trials sponsored by CSL Behring

Phase breakdown

Conditions studied

Recruiting trials led by CSL Behring

• A Phase 1b Study to Evaluate the PK of CSL300 (Clazakizumab) in Chinese Subjects With End Stage Kidney Disease (ESKD)
  NCT07619820 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
  NCT05485961 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1114 locations
• Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)
  NCT07224360 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 16 locations
• Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis
  NCT06699849 · Phase: Phase 2 · Ages: 12 Years and older · Sex: All (male and female) · 26 locations

Common questions

How many trials is CSL Behring recruiting for?

CSL Behring is the lead sponsor of 4 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.